ANAVEX LIFE SCIENCES CORP. (AVXL) research
ANAVEX LIFE SCIENCES CORP.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.40
- As of
ANAVEX LIFE SCIENCES CORP. (AVXL): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
As of . Source: SEC EDGAR filings for AVXL. Method and limitations.
Share the AVXL intelligence card
See AVXL live in the terminal
Track AVXL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live AVXL terminal, freeActive signals for AVXL
- highCONSENSUS_BUY
3 tracked funds increased AVXL this 2026Q2, institutional consensus
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in AVXL
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 54% of AVXL (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +157% to AVXL (2026Q2)
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in AVXL
FREE, NO ACCOUNT
Every signal on AVXL, as it fires
You are seeing 5 of 18 signals recorded on AVXL since 2026-05-26.
The five above landed across 2 days. The other 13 were recorded on 3 other days. 11 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AVXL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 032797300 · 2026Q2 | $7.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 032797300 · 2026Q2 | $852K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 032797300 · 2026Q2 | $408K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 032797300 · 2026Q2 | $299K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 032797300 · 2026Q2 | $157K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AVXL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AVXL against its peers
AVXL's return on equity of -48.9% ranks in the 40th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | AVXL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 20.2M | n/a | 16 |
| Operating margin | n/a | -354.5% | n/a | 16 |
| Net margin | n/a | -97.6% | n/a | 16 |
| Return on equity | -48.9% | -28.1% | 40 | 20 |
Peers (24): NGEN, ADAG, ALEC, KROS, PLX, IVVD, ELDN, YDES, IPHA, CHRS, PEPG, CUE, CGEN, NKTX, WHWK, ALXO, NAGE, TARA, SRZN, RNAC, ORMP, MSLE, CNTN, SLGL. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (AVXL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AVXL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AVXLand get the insider, 13F, options, and confluence read in one view.